Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027

Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027

Summary

Glioblastoma multiforme (GBM), otherwise known as Grade IV astrocytoma, is the most aggressive form of brain cancer and characterized as a disease with one of the highest unmet needs in oncology, with patients having a median overall survival (OS) between one and two years. The lack of approved therapies is mainly due to the inability of drugs to penetrate the blood-brain barrier (BBB). The only targeted agent approved for recurrent GBM patients is Roche’s Avastin (bevacizumab), approved in the US in 2008 and Japan in 2013 and used off-label in the 5EU and China. Otherwise, generic temozolomide in combination with radiotherapy makes up the majority of the GBM market and is considered the standard of care across the 8MM.

The GBM market is expected to experience modest growth in the 8MM (US, France, Germany, Italy, Spain, the UK, Japan, and urban China) from 2017-2027. This is driven by the launch of nine late-stage agents, primarily immunotherapies and small-molecules that can bypass the limitations of the BBB, which are expected to launch at premium-prices. In recent years, many late-stage agents were discontinued due to multiple factors. Developers will need to be astute in terms of their clinical development of novel therapies in order to secure approvals. Despite this, a myriad of opportunities remain in the GBM space with room for innovative therapies that are more efficacious than the current standard of care (SOC).

Key Questions Answered

- Which pipeline agents are the most promising and expected to launch in the 8MM? What are the forecast sales of these agents and what will be their impact in the GBM market?
- What are the main unmet needs in GBM, which pipeline drugs will fulfill these needs, and to what extent?
- What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?
- Key Opinions Leader (KOL) insights across the 8MM, relating to the current treatment options and opinions on the late- and early-stage pipeline agents.

Scope

- Overview of GBM, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized GBM therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in eight geographic regions, forecast from 2017 to 2027.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GBM therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for GBM. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global GBM market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global GBM market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GBM market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.